WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2006090413) NOVEL CRYSTALLINE FORM OF GEFITINIB AND A PROCESS FOR ITS PREPARATION
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2006/090413    International Application No.:    PCT/IN2006/000047
Publication Date: 31.08.2006 International Filing Date: 10.02.2006
IPC:
C07D 239/94 (2006.01), A61P 35/00 (2006.01), A61P 43/00 (2006.01)
Applicants: NATCO PHARMA LIMITED [IN/IN]; "NATCO House", Road NO.2, Banjara Hills, Hyderabad 500033, Andhra Pradesh (IN) (For All Designated States Except US).
JYOTHI PRASAD, Ramanadham [IN/IN]; (IN).
VENKAIAH CHOWDARY, Nannapaneni [IN/IN]; (IN)
Inventors: JYOTHI PRASAD, Ramanadham; (IN).
VENKAIAH CHOWDARY, Nannapaneni; (IN)
Priority Data:
150/CHE/2005 23.02.2005 IN
Title (EN) NOVEL CRYSTALLINE FORM OF GEFITINIB AND A PROCESS FOR ITS PREPARATION
(FR) NOUVELLE FORME CRISTALLINE DE GEFITINIB ET SON PROCEDE DE PREPARATION
Abstract: front page image
(EN)The present invention relates to a novel crystalline form of Gefitinib and a process for its Preparation thereof. Gefitinib is 4-(31-chloro-41-fluoro anilino)-7-methoxy-6- (3-morpholino propoxy) quinazoline and has the structural formula (I). The present invention is to provide a stable novel crystalline form of Gefitinib designated by us as Form-6, and a process for the preparation of the same. Gefitinib is useful in the treatment of a variety of solid tumors, especially non-small cell lung cancer and hematological malignancies.
(FR)La présente invention concerne une nouvelle forme cristalline de gefitinib et son procédé de préparation. Le gefitinib est une 4-(31-chloro-41-fluoro anilino)-7-méthoxy-6- (3-morpholino propoxy) quinazoline possédant une structure représentée par la formule générale (I). La présente invention concerne plus précisément une nouvelle forme cristalline stable de gefitinib dite « Forme-6 », ainsi que son procédé de préparation. Le gefitinib est utilisé pour le traitement de diverses tumeurs solides, en particulier du cancer bronchopulmonaire non à petites cellules et de malignités hématologiques.
Designated States: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)